JACC Case Reports asks whether GLP-1 agonists belong in vascular risk reduction

The wire

1. 01JACC: Case Reports published an item by Abuhalimeh and colleagues on October 8 framing GLP-1 receptor agonists as a potentially missing element of vascular risk reduction.
2. 02Cardiologists and prescribers tracking cardiovascular indications for semaglutide and related incretins will see this as case-level commentary rather than trial evidence.
3. 03Only the title and authorship are available; readers should treat any clinical inference as unsupported until the full case and its outcome data are reviewed.

From the source

Are GLP-1 Receptor Agonists the Missing Therapy in Vascular Risk Reduction?

JACC. Case reports · 2026 Oct 8 · Abuhalimeh BJ, Alhmouz MM, Rosheidat S et al.